BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/21/2018 8:24:21 AM | Browse: 320 | Download: 206
Publication Name World Journal of Immunology
Manuscript ID 41895
Country/Territory Israel
2018-08-30 01:45
Peer-Review Started
2018-08-30 06:17
To Make the First Decision
2018-10-22 00:35
Return for Revision
2018-10-24 09:17
2018-11-10 18:18
Second Decision
2018-11-29 07:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2018-11-29 23:30
Articles in Press
2018-11-29 23:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
2018-12-08 22:03
Typeset the Manuscript
2018-12-18 02:25
Publish the Manuscript Online
2018-12-21 08:24
ISSN 2219-2824 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Immunology
Manuscript Type Editorial
Article Title Cancer immunotherapy by targeting immune checkpoint receptors
Manuscript Source Invited Manuscript
All Author List Noah Isakov
Author(s) ORCID Number
Noah Isakov http://orcid.org/0000-0002-1412-0957
Funding Agency and Grant Number
Corresponding author Noah Isakov, PhD, Professor, Department of Microbiology, Immunology and Genetics, Ben-Gurion University, POB. 653, Beer Sheva 84105, Israel. noah@bgu.ac.il
Keywords Immune checkpoint; Immunotherapy; Cancer; Autoimmune diseases; T lymphocytes
Core Tip The major functions of immune checkpoint receptors are to maintain self-tolerance, prevent immunopathology, and regulate overall immune homeostasis. However, skewed activation of these receptors by cancer cells may lead to suppression of nascent anti-tumor immunity and promote tumor cell growth. Clinical studies demonstrated that blocking of inhibitory immune checkpoint receptors induced durable clinical responses and unprecedented therapeutic benefits in multiple types of malignancies. The present Editorial addresses some of the major immune checkpoint receptor targets in cancer immunotherapy, discusses some of the side effects and limitations in their utilization, and highlights some of the future challenges in the field.
Publish Date 2018-12-21 08:24
Citation Isakov N. Cancer immunotherapy by targeting immune checkpoint receptors. World J Immunol 2018; 8(1): 1-11
Url https://www.wjgnet.com/2219-2824/full/v8/i1/1.htm
DOI https://dx.doi.org/10.5411/wji.v8.i1.1
Full Article (PDF) WJI-8-1.pdf
Full Article (Word) WJI-8-1.doc
Manuscript File 41895-Review.docx
Answering Reviewers 41895-Answering reviewers.pdf
Audio Core Tip 41895-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 41895-Conflict-of-interest statement.pdf
Copyright License Agreement 41895-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 41895-Language certificate.pdf
Supplementary Material 41895-Supplementary-Material-revision.docx
Peer-review Report 41895-Peer-review(s).pdf
Scientific Misconduct Check 41895-Scientific misconduct check.pdf
Scientific Editor Work List 41895-Scientific editor work list.pdf